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ABSTRACT
Purpose To explore different allometric equations for scaling
clearance across the human life-span using propofol as a model
drug.
Methods Data from seven previously published propofol studies
((pre)term neonates, infants, toddlers, children, adolescents and
adults) were analysed using NONMEM VI. To scale clearance, a
bodyweight-based exponential equation with four different struc-
tures for the exponent was used: (I) 3/4 allometric scaling model;
(II) mixture model; (III) bodyweight-cut-point separated model;
(IV) bodyweight-dependent exponent model.
Results Model I adequately described clearance in adults and
older children, but overestimated clearance of neonates and
underestimated clearance of infants. Use of two different expo-
nents in Model II and Model III showed significantly improved
performance, but yielded ambiguities on the boundaries of the
two subpopulations. This discontinuity was overcome in Model
IV, in which the exponent changed sigmoidally from 1.35 at a
hypothetical bodyweight of 0 kg to a value of 0.56 from 10 kg
onwards, thereby describing clearance of all individuals best.
Conclusions A model was developed for scaling clearance over
the entire human life-span with a single continuous equation, in
which the exponent of the bodyweight-based exponential equation
varied with bodyweight.
KEY WORDS allometric . clearance . life-span .
pharmacokinetics . propofol
ABBREVIATIONS
BDE bodyweight-dependent exponent
EDTA ethylenediaminetetraacetic acid
NPDE normalized prediction distribution errors
RMSE root mean square error
INTRODUCTION
For scaling pharmacokinetics across the human life-span,
the 3/4 allometric scaling approach (1) has gained in pop-
ularity in the field of pediatrics. While the 3/4 allometric
scaling approach was originally designed to describe meta-
bolic rates between different species covering a wide range
in bodyweight (2), this function is now being applied to
parameterize the influence of changes in body size on drug
clearance parameters within the human weight-range.
In contrast with the reports supporting the 3/4 allometric
scaling principles (3–5), there is a number of theoretical
arguments against these scaling principles in general (6–8).
Furthermore, the value of the allometric exponent is debated
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(9,10), the existence of a unique and universal value for the
exponent is thought to be unlikely (11,12) and the application
of allometric scaling principles to pharmacokinetics in the
human weight-range is disputed (13,14). For paediatrics, the
covering of changes in body size made by this bodyweight-
based allometric equation with a fixed exponent of 0.75 for
clearance are specifically insufficient to describe and predict
drug clearance in preterm and term neonates, infants and
young children (13,15,16). When applying the 3/4 allometric
scaling method to different drugs, it has been found that the
model systematically over-predicted clearances for neonates
and under-predicted clearances for infants (15,17).
In order to account for the discrepancy of the 3/4 allome-
tric method in young children, an augmentation of the 3/4
allometric equation with an age-based sigmoidal equation has
been proposed (18,19). However, this age-adjustment is uni-
directional, whereas bi-directional changes from the 3/4 allo-
metric line have been reported in the papers aforementioned,
that depend on the age of the children (15,17). Furthermore,
introduction of this age-based maturation equation introduces
age into the model in addition to bodyweight. While age and
bodyweight are highly correlated in the paediatric population
in a nonlinear manner, this may result in a collinearity prob-
lem (20). In this respect, it is emphasized that recent research
shows that a priori inclusion of a false predefined covariate
relationship into a model may decrease the predictive perfor-
mance of that model (21). As a result of these limitations, in
some reports the exponent of the allometric scaling equation
was estimated instead of fixed to 0.75, resulting in values higher
than 1 in datasets of young infants (22,23). From these reports,
it seems that an optimized and statistically sound scaling ap-
proach is needed for scaling of clearance in paediatrics.
The aim of this study was to explore new approaches to
scale drug clearance over the entire human life-span. Pro-
pofol was used as a model drug, and for this study seven
datasets were available from preterm neonates with a me-
dian (range) gestational age of 37 (26–40) weeks to 81 year
old adults (15,24–29).
MATERIALS AND METHODS
Subjects
A total of 174 subjects from seven previously published
propofol studies were included in the current study. These
studies are described in detail elsewhere and are briefly
discussed as relevant to the current analysis.
Neonates (24)
Twenty-five cardiovascularly and respiratory stable neonates
with a median of bodyweight of 2.93 (range 0.68–4.03)
kilograms, postnatal age of 8 (1–25) days and gestational age
of 37 (26–40) weeks were given an intravenous bolus dose of
propofol (3 mg⋅kg−1) for the elective removal of chest tubes,
(semi)elective chest tube placement or endotracheal
intubation.
Infants (25)
Twenty-two non-ventilated infants after major craniofacial
surgery with a median bodyweight of 8.9 (4.8–12.5) kilo-
grams, aged 10 (3.8–17.3) months received 2–4 mg⋅kg−1·h−1
propofol during a median of 12.5 (6.0–18.1) hours.
Toddlers (26)
Twelve toddlers with minor burns, who had a median body-
weight of 11.2 (8.7–18.9) kilograms and age of 17.8 (12–31)
months, were administered 4 mg⋅kg−1 propofol just before
bathing.
Children (27)
Fifty-three healthy unpremedicated children with a median
bodyweight of 23.3 (15–60.5) kilograms and median age of 7
(3–11) years were studied. Twenty children received an intra-
venous loading dose of 3 mg⋅kg−1 propofol. In the remaining
33 children, an intravenous loading dose of 3.5 mg⋅kg−1 was
followed by amaintenance infusion. In 18 of the 33 children, a
single infusion rate of 0.15 mg⋅kg−1⋅min−1 was administered,
while 15 children received an infusion of 0.20 mg⋅kg−1⋅min−1
for 30 min, followed by an infusion of 0.125 mg⋅kg−1⋅min−1
till the end of the procedure.
Adolescents (15)
Fourteen adolescents with a median bodyweight of 51
(36.6–82) kilograms and median age of 14.7 (9.8–20.1) years
were anaesthetized with propofol-remifentanil (2–
10 mg⋅kg−1·h−1) for scoliosis surgery during 6.8 (3.3–7.7)
hours with an intra-operative wake-up test followed by re-
induction of anesthesia.
Adults I (28)
Twenty-four women undergoing gynaecological surgery,
with a median bodyweight of 68.5 (55–80) kilograms and a
median age of 45.5 (33–57) years, received 2.5 mg⋅kg−1
propofol over 60 s for induction of anesthesia.
Adults II (29)
Twenty-four healthy volunteers with a median bodyweight
of 79.4 (44.4–122.7) kilograms and median age of 53 (26–
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81) years were administered a bolus dose of propofol,
followed 1 h later by a 60 min infusion with an infusion
rate of 25, 50, 100, or 200 mg⋅kg−1·min−1 in a study
which investigated the influences of method of adminis-
tration, infusion rate, patient covariates, and EDTA
(ethylenediaminetetraacetic acid) on the pharmacokinet-
ics of propofol.
Pharmacokinetic Modeling
Model Building
The population pharmacokinetic analysis was performed
with the non-linear mixed effects modeling software NON-
MEM version 6.2. (ICON Development Solutions, Ellicott
City, MD, USA) using the first-order conditional estimation
method with the interaction option (FOCEI). Tools like S-
PLUS interface for NONMEM (LAP&P Consultants BV,
Leiden, NL), S-Plus (version 8.1, Insightful Software, Seat-
tle, WA, USA), XPose and R (version 2.10.0) were used to
visualize the output and evaluate the models.
Propofol concentrations were logarithmically trans-
formed and fitted simultaneously, since the range in con-
centrations was more than 1,000 fold. Model building was
performed in four steps: (1) selection of structural model, (2)
selection of statistical sub-model, (3) covariate analysis, (4)
model validation. A difference in objective function (OFV)
between models of more than 7.88 points was considered as
statistically significant (p<0.005 assuming a Chi-square dis-
tribution). Furthermore, the goodness-of-fit plots (observed
versus individual predicted concentrations and versus popula-
tion predicted concentrations, and conditional weighted
residuals versus time and versus population prediction concen-
trations) were evaluated (30). Finally, improvement of the
individual concentration-time profiles, the confidence inter-
vals of the parameter estimates and the correlation matrix
were assessed.
Structural Model
Based on previous reports (31–33) the time-course of
propofol concentrations was modeled with a three-
compartment model, which was parameterized in terms
of total clearance (CL), volume of distribution of the
central compartment (V1), volume of distribution of the
rapid-equilibrating peripheral compartment (V2) and
slow-equilibrating peripheral compartment (V3), and
inter-compartmental clearances between central com-
partment and two peripheral compartments (Q2,Q3).
In addition, the performance of a two compartment
model with the parameters CL, Q2, V1 and V2 was
evaluated.
Statistical Model
Inter-individual variability in the pharmacokinetic parameters
was tested in the model assuming log-normal distributions,
expressed as
θi ¼ θTV  eηi ; ηi  N ð0;w2Þ ð1Þ
where θi is the individual pharmacokinetic parameter value
for the ith individual, θTV is the population pharmacokinetic
parameter value or typical value, and ηi is a random variable
for the ith individual from a normal distribution with mean
zero and variance ω2. In addition to testing the inclusion of
inter-individual variability on individual parameters, model
improvement by inclusion of covariance between these
variability parameters was tested as well.
For the residual error, an additive model for log-
transformed concentrations was used which corresponds to
proportional error on untransformed data, expressed as:
logCij ¼ logCpred ij þ "; "  N ð0;σ2Þ ð2Þ
where Cij is the value of the observed propofol concentration
of ith individual at time j, Cpredij is the value of the predicted
propofol concentration of the ith individual at time j, and ε is
a random variable for this observation from a normal
distribution with mean zero and variance σ2.
Covariate Models
To visualize potential relationships, candidate covariates
such as age and bodyweight were plotted independently
versus the empirical Bayes post hoc estimates for all pharma-
cokinetic parameters. Potential covariates were separately
implemented into the model using a linear or power equation
over the studied covariate range:
θi ¼ θTV  ð CovCovMedianÞ
k ð3Þ
In this equation, θi represents the individual parameter
estimate of the ith subject, θTV represents the population
parameter estimate, Cov is the covariate of interest with
subscript median indicating the median value of the particular
covariate and k is the exponent which was fixed to 1 for a
linear function or estimated for a power function.
The significance of a covariate was statistically tested by
use of the objective function. A p value<0.005 was consid-
ered significant in the forward inclusion while on the other
hand a more stringent p value of<0.001 was used in the
backward deletion. In addition, individual and population
parameter estimates were plotted against the most predic-
tive covariate to evaluate whether the individual predicted
parameters are evenly distributed around the population
predicted values (30). When two or more covariates were
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found to significantly improve the model, the covariate caus-
ing the largest reduction in the objective function was retained
in the model and served as the basis for subsequent inclusion
of additional covariates. Furthermore, for the final covariate
model, general criteria for model evaluation were considered
as described under ‘Model Building’, while also the results of
the model validation procedures were taken into account.
As bodyweight proved to be superior over age as a
covariate for clearance, four covariate models based on
bodyweight were tested. For propofol clearance, the com-
mon structure of these allometric models was:
Cli ¼ Clp  BWi70
 k
ð4Þ
in which Cli is clearance in the ith individual with bodyweight
BWi; Clp is the clearance in a standardized adult with a body-
weight of 70 kg; and the exponent k has different values in the
four different covariate models as described below.
Model I. The 3/4 allometric model; in which k was fixed to
0.75.
Model II. Themixture model; in which different values for the
exponent k were estimated for two sub-populations. The
entire population was assumed to have two subpopulations:
POP1 and POP2. For each sub-population different k and Clp
values were estimated, but the inter-individual variability on
Cl was kept the same for both sub-populations. The assign-
ment of individuals to one of the sub-populations was deter-
mined by a probability model (34). Briefly, the probability
model assumed two log-normal distributions for clearance
with different mean values but common standard deviation
for two sub-populations. Each individual has a probability of π
belonging to POP1 and has 1-π probability of belonging to
POP2.The mixture model was implemented by the $MIX
option in NONMEM VI.
Model III. The bodyweight-cut-point separated model; in
which different values for the exponent k were estimated for
two sub-populations: POPbw<d and POPbw≥d. These sub-
populations were determined by a cut-point bodyweight d
which is a fixed effect parameter in NONMEM: individuals
with bodyweight less than the cut-point belonged to
POPbw<d and individuals with bodyweight greater than or
equal to the cut-point belonged to POPbw≥d.
Model IV. The bodyweight-dependent exponent (BDE)
model; in which the allometric exponent k changed in a
sigmoidal fashion with bodyweight according to Eq. 5:
k ¼ k0  kmax  BWi
g
kg50 þ BWig
ð5Þ
in which BWi is bodyweight of an individual i; k0 is the value
of the exponent at a theoretical bodyweight of 0 kg; kmax is
the maximum decrease of the exponent; k50 is the body-
weight at which a 50% decrease in the maximum decrease
of exponent is attained, and γ is the Hill coefficient deter-
mining the steepness of sigmoidal decline in the exponent.
Model Validation
Stratified bootstrap re-sampling was performed to obtain
the same numbers of patients of each of the seven study
populations in the new re-sampled datasets compared to the
original dataset. This stratified bootstrap was implemented
by the “bootstrap” command and the “-stratify_on” option
in Perl-speaks-NONMEM (copyright by Mats Karlsson,
Niclas Jonsson and Andrew Hooker). The median, standard
deviation and the 90% confidence interval of the parameter
estimates were calculated based on the results of the runs
that minimized successfully.
In addition, the normalized prediction distribution errors
(NPDE) method (35) was used as a simulation-based diag-
nostic. The dataset was simulated 2,000 times in NON-
MEM, each observed concentration was subsequently
compared to the simulated reference distribution using the
NPDE add-on package in R. A histogram of the NPDE
distribution in the total dataset and plots of NPDE versus
individual predicted concentration and versus time were used
to evaluate the final model.
In order to evaluate the precision of the population
predicted clearances by the four different covariate models
for clearance, we used the root mean square error (RMSE)
which was calculated as follows:
RMSE ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃP
n ðClp  CliÞ2
n
s
ð6Þ
%RMSE ¼ RMSE  100
MeanðCliÞ ð7Þ
in which Clp is the population predicted clearance; Cli is the
individual predicted clearance; n is the number of
individuals.
RESULTS
The analysis was based on a total number of 4,396 obser-
vations from 174 individuals aged between 1 day to 81 years
and with a bodyweight varying between 0.68 and 122.7 kg.
An overview of the datasets used for model building is
shown in Table I.
A three compartment model performed better than a
two compartment model. In this three compartment
model, four different bodyweight-based allometric equa-
tions for clearance were seperately tested and evaluated
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for their performance. All parameter estimates including
their coefficients of variation (CV values) and objective
functions of these four covariate models are listed in
Table II.
The 3/4 allometric model (Model I) with a fixed allome-
tric exponent of 0.75 had an OFV of −2339.7 (Table II).
With this model population values of propofol clearance in
children weighing less than 15 kg, were both over-estimated
(in children between 0.5 and 5 kg) and under-estimated (in
children between 5 and 15 kg) (Fig. 1).
For the mixture model (Model II) the OFV decreased
significantly (p<0.001) compared to Model I (Table II).
The estimated allometric exponent value for clearance
of population POP1 was less than 1 (0.676), whereas its
value for clearance of population POP2 was greater than
1 (1.321) (Table II). The probability of an individual
belonging to POP1 (π) in Model II was found to be 0.2.
Figure 1 shows that the population line of Model II
described the post hoc propofol clearances better than
Model I.
The bodyweight-cut-point separated model (Model III)
had an OFV of −2464.4, which was an increase of 21.8 (P<
0.001) points compared to Model II and a decrease of 124.7
points (p<0.001) compared to Model I (Table II). The
bodyweight cut-point was estimated to be 16.5 kg, which
was fixed to this value later on to obtain a successful covari-
ance step. The estimated exponents of populations POPbw<d
and POPbw≥d were 1.68 and 0.614, respectively (Table II).
Figure 1 shows that Model III results in improved the fit of
the population line to the post hoc clearances compared to
Model I.
The bodyweight-dependent exponent model (Model IV)
had the lowest OFV of −2,489 of the four allometric cova-
riate models, which was significantly superior over the 3/4
allometric model and the bodyweight-cut-point separated
model (p<0.001) (Table II). The OFV of this model was not
significantly different from the OFV of the mixture model.
In order to get a successful covariance step, the exponent of
bodyweight at 0 kg (k0) and the hill factor (γ) were fixed to
the estimated values from a successful run without covari-
ance step, which were 1.35 and 5.24, respectively. Visually,
Model IV had the best overall distribution of post hoc clear-
ances versus population clearance (Fig. 1). Finally, model IV
had the lowest inter-individual variability in clearance
(Table II), indicating that this new equation indeed accounts
for variability in clearance in the entire range of bodyweight
of the subjects.
Table III lists the%RMSE values for the different
paediatric subpopulations for all four covariate models.
The precision of clearance prediction shows a trend of
decrease from adult population to neonate population
for the four models. In neonates, infants, and children,
the bodyweight-dependent exponent model (Model IV)
had the lowest%RMSE, and thus the highest precision,
of the four models. In toddlers, the mixture model
(Model II) had the lowest%RMSE value compared to
other models.
Based on these results, Model IV was selected as cova-
riate model and further optimized. The parameter estimates
of the final PK model are listed in Table IV. Figure 2 shows
how the bodyweight dependent exponent for clearance (k,
Eq. 5) changes with bodyweight according to the estimated
parameters of Eq. 5 in Table IV. The figure shows that k
decreased from a highest value of 1.35 (k0) at the theoretical
bodyweight zero to a lowest value of 0.65 (k0-kmax). At a
bodyweight of 3.78 kg (k50), half of the maximum decrease
was reached (Table IV). The Hill coefficient (γ) of 5.24
reflected the rapid decrease in the exponent (k) with body-
weight (Fig. 2).Concerning other parameters than clearance,
a linear function for bodyweight on V1 for the children who
Table I Overview of Propofol Pharmacokinetic Datasets Used in the Current Analysis (Values Expressed as Median (Range))
Population N Indication Weight (kg) Age (yrs) Administration Samplesc
Neonates (24) 25 Removal of chest tubes 2.93(0.68–4.03) 8(1–25)a Bolus 4–14
Infants (25) 20 Post-operative sedation after 9(4.8–12.5) 10.2(3.8–17.3)b Infusion 4–15
craniofacial surgery
Toddlers (26) 12 Bathing of patients with minor burn injuries 11.2(8.74–18.9) 1.25(1–2.6) Bolus 11–12
Children (27) 53 Superficial body surface surgery 23.3(15–60.5) 7(3–11) Bolus&infusion 5–18
Adolescents (15) 14 Scoliosis surgery 51(36.6–82) 14.5(9.6–19.8) Bolus&infusion 6–21
Female adults(28) 24 Gynecological surgery 68.5(55–80) 45.5(33–57) Bolus 18
Adults (29) 24 PK study in healthy volunteers 79.4(44.4–122.7) 53(26–81) Infusion 20–21
a age in days
b age in months
c number of samples per subject (range)
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were younger than 100 days was identified, while for V2 a
power equation based on bodyweight was found. Inclusion
of these covariates resulted in a further decrease of 91.7
point (p<0.001) in the OFV compared to Model IV. The
observed versus population predicted plots stratified by study
in Fig. 3 confirm that the final model not only describes the
study population as a whole, but also the individual study
populations without bias. Results of the bootstrap analysis
show that the median estimated values based on resampled
data were close to the estimated values from the final model
fit of the original data and that all CV percentages are below
50%. This suggests the final model to be stable and the
estimated parameter values to be accurate and precise.
The results of the bootstrap are of particular relevance for
Table II Parameter Values,
Corresponding Coefficients of
Variation (CV%), and Objective
Function for the Four Different
Covariate Models for Clearance.
Model I: 3/4 Allometric Model;
Model II: the Mixture Model;
Model III: the Bodyweight-Cut-
Point Separated Model; Model IV:
the Bodyweight-Dependent Ex-
ponent (BDE) Model
bw0bodyweight; π 0 the proba-
bility of the individuals belonging to
POP1 in the mixture model
(Model II); d 0 the cut-point in
bodyweight dividing the two sub-
populations in the bodyweight-
cut-point separated model (Model
III); k00 value of the exponent at a
theoretical bodyweight of 0 kg;
kmax0 the maximum decrease of
the exponent; k500 the body-
weight at which a 50% decrease in
the maximum decrease of expo-
nent is attained; γ0 the Hill coeffi-
cient determining the steepness of
sigmoidal decline in the exponent
Parameter Model
Model I Model II Model III Model IV
Fixed effect
Cl (L/min) 0 Clp⋅(bw/70)
0.75 0 Clp⋅(bw/70)
k 0 Clp⋅(bw/70)
k 0 Clp⋅(bw/70)
k
Clp (L/min∙70 kg) 1.88(5.3%) 1.99(2.5%)
Clp (L/min∙70 kg)
of POP1 2.52(9.7%)
of POP2 2.13(3.8%)
Clp (L/min∙70 kg)
of POPbw<d 15.4(29.3%)
of POPbw≥d 2.03(2.8%)
k
of POP1 1.32(4.2%)
of POP2 0.68(8.9%)
k
of POPbw<d 1.68(8.4%)
of POPbw≥d 0.61(5.9%)
π (i01) 0.2(27.7%)
d (kg) 16.5 FIX
k ¼ k0  kmax  bwg=ðk50g þ bwgÞ
k0 1.35 FIX
kmax 0.79(8.5%)
k50 (kg) 3.71(7.4%)
γ 5.1 FIX
Q2(L/min) 1.81 (6.2%) 1.82 (6.3%) 1.8 (6.2%) 1.76 (6.6%)
Q3 (L/min) 0Q3p⋅(bw/70) 0Q3p⋅(bw/70) 0Q3p⋅(bw/70) 0Q3p⋅(bw/70)
Q3p (L/min∙70 kg) 1.55 (4.8%) 1.54(4.8%) 1.55 (4.8%) 1.59 (5.5%)
V1 (L) 5.18 (10.6%) 4.94 (11.4%) 5.06 (11.1%) 4.9 (11.8%)
V2 (L) 0V2p∙(bw/70) 0V2p∙(bw/70) 0V2p∙(bw/70) 0V2p∙(bw/70)
V2p (L/70 kg) 23.9 (10.5%) 23.4 (10.8%) 23.1 (10.7%) 23.9 (10.4%)
V3 (L) 0V3p⋅(bw/70) 0V3p⋅(bw/70) 0V3p⋅(bw/70) 0V3p⋅(bw/70)
V3p (L/70 kg) 228 (6.8%) 219 (7.0%) 216 (7.0%) 226 (8.6%)
Inter-individual variability
ω2 CL 0.44(20.7%) 0.11 (17.4%) 0.21 (24.5%) 0.08(17.1%)
ω2 V1 1.55(15.2%) 1.52(16.0%) 1.53(15.9%) 1.53(16.3%)
ω2 Q3 0.23(14.5%) 0.22(16.3%) 0.22(15.7%) 0.27(20.1%)
ω2 V2 0.81(11%) 0.82 (11.4%) 0.81(11.4%) 0.82(11.5%)
ω2 V3 0.3(17.4%) 0.31(17.8%) 0.32(17.4%) 0.76(39.3%)
Residual error
σ2 additive 0.06(10.1%) 0.06(10.2%) 0.06(10.3%) 0.06(10.3%)
OFV −2339.7 −2486.2 −2464.4 −2,489
Bodyweight-Dependent Allometric Exponent for Scaling Clearance 1575
the parameters that were fixed in model IV, i.e. k0 and γ, as
they justify the actual value these parameters were fixed to.
Furthermore, the results from the normalized prediction
distribution errors (NPDE) analysis in Fig. 4 show that the
model can predict the median concentration in the overall
dataset accurately, even though there is a slight over-
prediction of the variability in the model. Finally, no trend
in the plots of NPDE versus time and predicted concentration
were observed.
Figure 5 shows how variation in the parameters k0,
kmax, k50, and γ of the bodyweight dependent exponent k
of Eq. 5 results in different curves for clearance versus
bodyweight, including the observed curve in the current
analysis on propofol clearance. This figure illustrates
that the developed bodyweight-dependent exponent
model is capable of capturing different maturation pro-
files of clearance versus bodyweight allowing in principle
to be applied to different drugs and/or different metabolic
pathways.
Fig. 1 Plots of post hoc and population clearance values versus bodyweight. For the 3/4 allometric model (Model I), ○: individual post hoc clearances, solid
line: population predicted clearance curve; the mixture model (Model II), ■: individual post hoc clearances of POP1, ○: individual post hoc clearances of
POP2, dashed line: population predicted clearance curve of the POP1, solid line: population predicted clearance curve of POP2; the bodyweight-cut-point
separated model (Model III), ■: individual post hoc clearances of POPbw<d, ○: individual post hoc clearances of POPbw≥d, dashed line: population predicted
clearance curve of the POPbw<d, solid line: population predicted clearance curve of POPbw≥d; the bodyweight-dependent exponent (BDE) model (Model
IV), ○: individual post hoc clearances, solid line: population predicted clearance curve.
Table III %RMSE of the Four Bodyweight-Based Exponential Equations
for the Different Human Subpopulations, Model I: 3/4 Allometric Model;
Model II: the Mixture Model; Model III: the Bodyweight-Cut-Point Sepa-
rated Model; Model IV: the Bodyweight-Dependent Exponent (BDE)
Model
Population Model I
(%)
Model II
(%)
Model III
(%)
Model IV
(%)
Neonates 160 149 61 49
Infants 63 41 53 40
Toddlers 25 37 38 33
Children 32 26 26 23
Adolescents 24 53 30 27
Adults I & II 24 26 21 20
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DISCUSSION
In this study, we tested four different allometric equations to
capture changes in propofol clearance in seven datasets
comprising almost every stage of human life. We found that
fixing the allometric exponent to 0.75 (the 3/4 allometric
model, Model I) resulted in adequate description of clear-
ance in adults, adolescents, children and toddlers, but
yielded significant under-prediction in infants and over-
prediction in term and preterm neonates. Results of the
mixture model (Model II) and the bodyweight-cut-point
separated model (Model III) showed that an allometric
Table IV Parameter Estimates,
Bootstrap Results and Their
Corresponding Coefficients of
Variation (CV%) Values for the Fi-
nal PK Model
aMean estimated parameter values
and their coefficient of variation in
percentage from 200 stratified
bootstrapping re-samples
bw0bodyweight; k00 the expo-
nent at a theoretical bodyweight
of 0 kg; kmax0 the maximum de-
crease of the exponent; k500 the
bodyweight at which a 50% de-
crease in the maximum decrease
of exponent is attained; γ0 the Hill
coefficient determining the steep-
ness of sigmoidal decline in the
exponent; m 0 the exponent of
bodyweight on V2
Parameter Final model Bootstrapa
Fixed effect
Cl (L/min) 0 Clp∙(bw/70)
k 0 Clp∙(bw/70)
k
Clp (L/min∙70 kg) 2.02(2.6%) 2.02(2.5%)
k ¼ k0  kmax  bwg=ðk50g þ bwgÞ
k0 1.34 FIX 1.35(6.2%)
kmax 0.79(12.2%) 0.80(10.7%)
k50 (kg) 3.78(15.1%) 3.75(7.5%)
γ 5.24 FIX 5.25(41.6%)
Q2(L/min) 1.77(6.3%) 1.72(7.9%)
Q3 (L/min) 0Q3p⋅(bw/70) 0Q3p⋅(bw/70)
Q3p (L/min∙70 kg) 1.65(5.0%) 1.64 (4.8%)
V1 (L) if PNA≥100 then0V1p, if PNA<100 then0V1p⋅(bw/70)
V1p (L) 7.58(12.4%) 7.69(10.1%)
V2 (L) 0V2p∙(bw/70)
m 0V2p∙(bw/70)
m
V2p (L/70 kg) 15.5(14.7%) 15.7 (11.4%)
m 0.55(17.5%) 0.55(10.8%)
V3 (L) 0V3p⋅(bw/70) 0V3p⋅(bw/70)
V3p (L/70 kg) 221(8.9%) 225(8.9%)
Inter-individual variability
ω2 CL 0.09(18.0%) 0.08(19.4%)
ω2 V1 1.19(41.3%) 1.22 (18.3%)
ω2 Q3 0.25(17.0%) 0.26(19.9%)
ω2 V2 0.52(40.8%) 0.54(16.6%)
ω2 V3 0.71(44.0%) 0.75(46%)
Residual error
σ2 additive 0.06(10.3%) 0.06 (10.1%)
OFV −2580.7
Fig. 2 The relationship between
the allometric exponent k and
bodyweight in the bodyweight-
dependent exponent (BDE)
model for clearance (Model IV,
Eq. 5). The parameter k0 repre-
sents the value of the exponent at
a theoretical bodyweight of 0 kg,
kmax represents the maximum
decrease of the exponent, k50
represents bodyweight at which
50% of the maximum decrease
in the exponent is attained, and γ
represents the Hill coefficient that
determines the steepness of the
sigmoidal decline.
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exponent other than 0.75 was more suitable for neonates
and infants. In fact, both models identified an allometric
exponent greater than 1 for the subpopulation that was
composed of mainly neonates and infants resulting in im-
proved description of clearance in these youngest and light-
est patient groups in comparison with the 3/4 allometric
model. This has been reported before for morphine clear-
ance in children younger than 3 years of age, where an
exponent of 1.44 was found to best describe the develop-
mental changes in clearance (22). Similarly, Mahmood
reported that the error in the prediction of clearance de-
creased when the scaling exponent increased from 0.75
towards 1 when studying different drugs in children less
than 1 year of age (13). Even though the overall perfor-
mance improved significantly, the use of two different allo-
metric exponents for different human subpopulations as
implemented in Model II and Model III resulted in ambig-
uous clearance predictions for the individuals on the bound-
aries of the paediatric subpopulations. In the current study,
the observed issue of different exponents at different weight
ranges was overcome by implementing an allometric equa-
tion with an exponent that varies with bodyweight. This
bodyweight-dependent exponent (BDE) model contains a
continuous bodyweight-based equation which allowed for
the description of maturational changes in propofol clear-
ance in individuals covering the entire human life-span.
While the current model needs to be further evaluated in
an external validation procedure, according to the advanced
model evaluation criteria for pediatric population models
(30), the descriptive and predictive performances of this
model were affirmed by stratified diagnostics (Fig. 3), boot-
strap validation (Table IV), NPDE (Fig. 4), and%RMSE
results (Table III).
An important question is whether this bodyweight-
dependent exponent may reflect underlying physiological
maturation processes. Unfortunately, we were not able to
establish a direct link between the change in exponent and
the physiological maturation process, due to the lack of
physiological information in our data. The results of this
study are therefore to be compared to other studies. The
Fig. 3 Observed versus
population predicted propofol
concentrations of the
bodyweight-dependent exponent
model (Model IV). ‘All’ presents
data of all datasets together. Oth-
er panels represent data of neo-
nates (24), infants (25), toddlers
(26), children (27), adolescents
(15), adults I (28) and adults II
(29).
Fig. 4 NPDE results of the final PK model for propofol. Left panel: histogram of NPDE distribution in the full dataset with the solid line representing a
normal distribution as a reference; Middle panel: NPDE versus time; Right panel: NPDE versus log transformed concentration.
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reported high value of the exponent at very low bodyweights
(Fig. 2), is the result of rapid changes in propofol clearance
with bodyweight at these young age ranges (Fig. 1, model
IV). The lower value for the exponent at higher weight
ranges, results from the accomplishment of the maturation
process of propofol clearance (Fig. 2). According to the well-
stirred model, hepatic clearance is determined by hepatic
extraction ratio and liver blood flow. As propofol is a drug
with a high extraction ratio, systemic clearance is driven by
liver blood flow (36,37). While there are no good data on
hepatic blood flow in relation to age, hepatic blood flow in
infants was suggested to be comparable to adult values.
Therefore maturation of metabolic capacity could be con-
sidered the cause of the rapid changes in clearance in the
young individuals (38). For propofol, glucuronidation by the
UGT1A9 isoenzyme is the major elimination pathway.
UGT1A9 was reported to undergo an age-dependent quan-
titative differential regulation extending up to 24 months of
age (39), and it was found that only part of the reduced
glucuronidation rate was compensated by hydroxylation in
neonates (40). Even though this cannot be proven, it can be
speculated that the rapid change in the bodyweight-
dependent exponent at low bodyweight ranges may be the
result of the change in the capacity of the UGT1A9
isoenzyme.
In recent years, there has been a debate on how body-
weight and age, which are two correlated covariates in the
paediatric population, should be included in population phar-
macokinetic models. It has been proposed that the 3/4 allo-
metric equation can be used to standardize drug clearance to
the average adult bodyweight of 70 kg, after which age-based
equations can be added to account for maturational differ-
ences in the younger populations compared to the older ones
(1,41). These age based functions are needed because poor
prediction performance of the 3/4 allometric model can be
expected when scaling clearance to children under a certain
age (15–17). However, this addition of age to the 3/4 allome-
tric bodyweight based scaling function may result in collinear-
ity. The effect of the collinearity on parameter estimates in
nonlinear mixed effect models has already been studied and it
was found that high collinearity between predictors, defined as
data collinearity, increased the bias of the parameter estimates
and enlarged the corresponding standard errors (20). More
recently, it has been shown that when one of two correlated
covariates that contain information about a model parameter
is pre-selected over the other, the predictive performance of
the resulting model may be diminished, unless the pre-selected
covariate relationship reflects the true biological relationship
(21). With the great amount of theoretical and experimental
evidence against the 3/4 allometric model (6–12,14), and the
risk of collinearity when introducing age to correct for devia-
tions from this model, new scaling approaches are needed.
The bodyweight-dependent exponent model we de-
scribed in this paper are of particular relevance for scaling
clearance parameters to the youngest age ranges including
infants, term and preterm neonates. Since in these age
groups changes in the pharmacokinetics may be expected
to be large, there is currently great interest in scaling clear-
ance parameters from older populations to neonates or
infants younger than 2 years of age (15,16,42). It is however
uncertain whether the parameters of the bodyweight-
dependent exponent model we developed for propofol can
be generalized to other drugs. Propofol has very specific
characteristics such as a high extraction ratio, direct glucur-
onidation and high lipophilicity. However, as Fig. 5 shows,
the function is very flexible, and in our opinion the proposed
Fig. 5 Simulations for the
bodyweight-dependent exponent
(BDE) model (Model IV) on the
basis of different values for the
parameters of Model IV (Eq. 5).
Solid black curve: BDE curve with
k001.34, kmax00.79, k50 03.78,
γ05.24 (final PK model); dashed
grey curve: BDE curve with k00
1, kmax00.4, k5003.78, γ05;
long dash short dash grey curve:
BDE curve with k001.7, kmax0
0.8, k5003.78, γ05; short dash
dot grey curve: BDE curve with
k001.4, kmax01.1, k5004.5,
γ010; medium dash double dot
grey curve: BDE curve with
k001.34, kmax00.8, k5001,
γ05.
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model can be applied to other drugs provided data in young
children are available to estimate the exact parameters of
Eq. 5 of the bodyweight dependent exponent model for that
drug.
CONCLUSION
In this study, we have developed a model for scaling propo-
fol clearance over the entire human life-span with a single
continuous bodyweight based equation, in which the expo-
nent of the equation varies with bodyweight. The flexibility
of this bodyweight-dependent exponent (BDE) model may
increase the applicability of this type of models to scale
clearance of other drugs over large parts of the human
life-span. This function may provide an alternative for
allometric scaling approaches in the extrapolation of drug
clearances from older to younger human age-ranges.
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